PDS Biotechnology (PDSB)
(Real Time Quote from BATS)
$3.12 USD
+0.08 (2.63%)
Updated Jun 27, 2024 12:43 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Income Statements
Fiscal Year end for PDS Biotechnology Corporation falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 43 | 42 | 21 | 15 | 21 |
Income After Depreciation & Amortization | -43 | -42 | -21 | -15 | -21 |
Non-Operating Income | 3 | 1 | 0 | 0 | 14 |
Interest Expense | 4 | 1 | 0 | 0 | 0 |
Pretax Income | -44 | -42 | -21 | -15 | -7 |
Income Taxes | -1 | -1 | -5 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -43 | -41 | -17 | -15 | -7 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -43 | -41 | -17 | -15 | -7 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -42 | -41 | -21 | -15 | -21 |
Depreciation & Amortization (Cash Flow) | 1 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -43 | -42 | -21 | -15 | -21 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 30.95 | 28.60 | 25.60 | 16.75 | 4.87 |
Diluted EPS Before Non-Recurring Items | -1.39 | -1.43 | -0.84 | -0.89 | -3.57 |
Diluted Net EPS (GAAP) | -1.39 | -1.43 | -0.66 | -0.89 | -1.44 |
Fiscal Year end for PDS Biotechnology Corporation falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 10.09 | 10.41 | 10.52 | 12.69 | 9.42 |
Income After SG&A, R&D, and Dept/Amort Expenses | -10.09 | -10.41 | -10.52 | -12.69 | -9.42 |
Non-Operating Income | 0.67 | 0.68 | 0.74 | 0.75 | 0.73 |
Interest Expense | 1.17 | 1.17 | 1.07 | 1.00 | 0.97 |
Pretax Income | -10.60 | -10.90 | -10.85 | -12.94 | -9.66 |
Income Taxes | 0.00 | 0.00 | 0.00 | -1.41 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -10.60 | -10.90 | -10.85 | -11.53 | -9.66 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -10.60 | -10.90 | -10.85 | -11.53 | -9.66 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | 34.82 | 31.67 | 30.91 | 30.80 | 30.43 |
Diluted EPS Before Non-Recurring Items | -0.30 | -0.34 | -0.35 | -0.37 | -0.32 |
Diluted Net EPS (GAAP) | -0.30 | -0.35 | -0.35 | -0.37 | -0.32 |